Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12950313 | 0.98 | ACHE (0.59) | ACHECHRM5ADRA2CKDM4EL3MBTL1 | |
| SCHEMBL12717548 | 0.92 | ACHE (0.50) | ACHECHRM5ADRA2CKDM4EL3MBTL1 | |
| SCHEMBL21120881 | 0.92 | ACHE (0.50) | ACHECHRM5ADRA2CKDM4EL3MBTL1 | |
| SCHEMBL10685124 | 0.92 | ACHE (0.50) | ACHECHRM5ADRA2CKDM4EL3MBTL1 | |
| SCHEMBL14197722 | 0.90 | ACHE (0.77) | ACHECHRM5ADRA2CKDM4ESIGMAR1 | |
| SCHEMBL10130225 | 0.88 | ACHE (0.73) | ACHECHRM5ADRA2CKDM4ESIGMAR1 | |
| SCHEMBL10998970 | 0.88 | ACHE (0.73) | ACHECHRM5ADRA2CKDM4ESIGMAR1 | |
| SCHEMBL21064051 | 0.84 | ACHE (0.88) | ACHECHRM5ADRA2CKDM4ECHRM2 | |
| SCHEMBL20756545 | 0.83 | ACHE (0.67) | ACHECHRM5ADRA2CKDM4ESIGMAR1 | |
| SCHEMBL12827 | 0.83 | ACHE (0.43) | ACHECHRM5ADRA2CKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946259-B2 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140066477-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-03-06 | — | — | US | disclosed |
| US-8598353-B2 | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-12-03 | — | — | US | disclosed |
| EP-1863771-B1 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2012-11-07 | — | — | EP | disclosed |
| EP-2457901-A1 | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors | High Point Pharmaceuticals, LLC (US) | 2012-05-30 | — | — | EP | disclosed |
| US-7985764-B2 | Amide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-26 | — | — | US | disclosed |
| US-7985764-B2 | Amide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-26 | — | — | US | disclosed |
| US-20110065713-A1 | Benzazole Derivatives, Compositions, and Methods of Use as B-Secretase Inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-03-17 | — | — | US | disclosed |
| US-7893267-B2 | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | VTVX HOLDINGS II LLC | 2009-12-31 | — | — | US | disclosed |
| US-20090062363-A1 | AMIDE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090062363-A1 | AMIDE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1988076-A1 | AMIDE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-05 | — | — | EP | disclosed |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | ACHE 20/4885CHRM5 3452/4885ADRA2C 1588/4885 |
| US-20110065713-A1 | Benzazole Derivatives, Compositions, and Methods of Use as B-Secretase Inhibitors | BACE1, BACE2, APP | ACHE 27/4885CHRM5 3277/4885ADRA2C 1996/4885 |
| US-20090062363-A1 | AMIDE DERIVATIVE OR SALT THEREOF | HTR7, HTR2B, NPSR1 | ACHE 2865/4885CHRM5 860/4885ADRA2C 236/4885 |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | BACE1, BACE2, APP | ACHE 20/4885CHRM5 3452/4885ADRA2C 1588/4885 |
| US-20140066477-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | ACHE 20/4885CHRM5 3452/4885ADRA2C 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.